Entera Bio (ENTX) Competitors $2.22 +0.08 (+3.74%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.16 -0.06 (-2.48%) As of 10/24/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. NGNE, EOLS, BNTC, AMRN, RCKT, KRRO, KMDA, IVVD, AURA, and REPLShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Neurogene (NGNE), Evolus (EOLS), Benitec Biopharma (BNTC), Amarin (AMRN), Rocket Pharmaceuticals (RCKT), Korro Bio (KRRO), Kamada (KMDA), Invivyd (IVVD), Aura Biosciences (AURA), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors Neurogene Evolus Benitec Biopharma Amarin Rocket Pharmaceuticals Korro Bio Kamada Invivyd Aura Biosciences Replimune Group Entera Bio (NASDAQ:ENTX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Do institutionals and insiders believe in ENTX or NGNE? 14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by insiders. Comparatively, 11.6% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ENTX or NGNE more profitable? Neurogene has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Neurogene's return on equity of -33.33% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Entera Bio-4,525.11% -77.75% -68.13% Neurogene N/A -33.33%-30.34% Do analysts rate ENTX or NGNE? Entera Bio presently has a consensus target price of $10.00, indicating a potential upside of 350.45%. Neurogene has a consensus target price of $46.17, indicating a potential upside of 54.46%. Given Entera Bio's higher possible upside, equities analysts clearly believe Entera Bio is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50Neurogene 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has better earnings and valuation, ENTX or NGNE? Entera Bio has higher earnings, but lower revenue than Neurogene. Entera Bio is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$180K563.14-$9.54M-$0.26-8.54Neurogene$930K458.63-$75.14M-$4.31-6.94 Does the media favor ENTX or NGNE? In the previous week, Entera Bio had 5 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Entera Bio and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.91 beat Entera Bio's score of 1.00 indicating that Neurogene is being referred to more favorably in the news media. Company Overall Sentiment Entera Bio Positive Neurogene Very Positive Which has more volatility & risk, ENTX or NGNE? Entera Bio has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. SummaryNeurogene beats Entera Bio on 10 of the 17 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.37M$3.46B$6.22B$10.81BDividend YieldN/A2.28%5.72%4.81%P/E Ratio-8.5428.2931.5030.91Price / Sales563.14497.18594.92133.93Price / CashN/A46.9537.2561.86Price / Book9.6510.4012.056.61Net Income-$9.54M-$52.83M$3.34B$277.10M7 Day Performance-5.53%2.10%1.93%2.57%1 Month Performance24.02%12.33%7.77%3.79%1 Year Performance18.09%14.14%56.40%33.01% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio2.1033 of 5 stars$2.22+3.7%$10.00+350.5%+22.0%$101.37M$180K-8.5420News CoveragePositive NewsAnalyst ForecastNGNENeurogene1.8612 of 5 stars$32.16+10.8%$46.17+43.6%-38.0%$414.32MN/A-7.4690Analyst ForecastEOLSEvolus4.1196 of 5 stars$6.69+4.5%$21.25+217.6%-57.0%$413.99M$266.27M-6.83170BNTCBenitec Biopharma1.6657 of 5 stars$16.23+3.7%$24.80+52.8%+51.1%$410.82M$80K-11.0420News CoverageAnalyst ForecastAMRNAmarin0.9759 of 5 stars$20.25+3.1%$12.00-40.7%+71.5%$406.21M$228.61M-5.52360News CoverageUpcoming EarningsAnalyst ForecastRCKTRocket Pharmaceuticals4.9001 of 5 stars$4.00+7.8%$16.67+316.7%-77.6%$400.32MN/A-1.59240Analyst ForecastGap UpKRROKorro Bio2.5571 of 5 stars$46.35+10.0%$86.83+87.3%-44.1%$395.83M$2.27M-4.7570Gap UpKMDAKamada4.6789 of 5 stars$7.08+4.9%$13.00+83.6%+29.3%$388.16M$160.95M20.82360News CoveragePositive NewsAnalyst ForecastIVVDInvivyd4.1748 of 5 stars$1.97+13.2%$5.14+160.8%+125.5%$373.07M$46.21M-2.14100Positive NewsAURAAura Biosciences1.9486 of 5 stars$6.06+6.9%$20.50+238.3%-47.9%$352.22MN/A-3.0950REPLReplimune Group4.3729 of 5 stars$8.94+98.7%$11.00+23.0%-26.4%$351.25MN/A-2.76210Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Neurogene Competitors Evolus Competitors Benitec Biopharma Competitors Amarin Competitors Rocket Pharmaceuticals Competitors Korro Bio Competitors Kamada Competitors Invivyd Competitors Aura Biosciences Competitors Replimune Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
